# A Study of Brentuximab Vedotin, Rituximab, and Dose Attenuated CHP in Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

> **NCT02734771** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Patrick Reagan** · enrollment: 24 (estimated)

## Conditions studied

- Diffuse Large B-Cell Lymphoma

## Interventions

- **DRUG:** Brentuximab vedotin
- **DRUG:** Rituximab
- **DRUG:** Cyclophosphamide
- **DRUG:** Doxorubicin
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT02734771
- **Lead sponsor:** Patrick Reagan
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-06
- **Primary completion:** 2025-12
- **Final completion:** 2025-12
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2025-08-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02734771

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02734771, "A Study of Brentuximab Vedotin, Rituximab, and Dose Attenuated CHP in Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02734771. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*